Portugal's 2001 drug decriminalisation law was greeted, at the time, with predictions of social catastrophe. Twenty-four years of public health data — showing falls in overdose deaths, HIV transmission, and incarceration — have made it instead the most-studied drug policy reform in modern European history. The government's decision to go further is grounded in the same empirical habit of mind.
The Therapeutic Psychedelics Regulatory Framework, in force since January 2025, authorises licensed clinical settings to administer psilocybin (the active compound in certain mushroom species) and MDMA (the active compound in ecstasy) as adjuncts to structured psychotherapy sessions. Treatment is restricted to diagnosed treatment-resistant major depression, post-traumatic stress disorder, and end-of-life anxiety — indications where Phase III trial data from the United States and Switzerland had already established efficacy profiles compelling enough to generate FDA Breakthrough Therapy designations.
The 18 licensed clinics, distributed across Lisbon, Porto, and the Algarve, are staffed by certified therapist pairs — one to administer pharmacological support, one to conduct the psychotherapy session — working to a national protocol developed by the Calouste Gulbenkian Foundation in collaboration with Johns Hopkins and Imperial College London research teams.
National health insurance (SNS) covers 70 percent of treatment costs for patients meeting clinical criteria, with means-tested top-ups available for low-income patients. A national registry of outcomes, mandatory for all licensed providers, will feed into a five-year evidence review that will determine whether the framework is expanded, maintained, or modified.
"We did not legalise anything," said Health Minister Ana Paula Martins. "We followed the evidence to where it led. That is what health policy is for."